ArticleOsteoarthritis and cartilage open2026
Baseline pain medication is associated with longer duration of high adherence in a three-month digital treatment program for hip and knee osteoarthritis.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate whether baseline use of pain medication is associated with program adherence during a three-month digital treatment program for individuals with hip or knee osteoarthritis (OA). Design: An observational cohort study using registry data on weekly participant adherence from 33078 participants enrolled in a digital education and exercise therapy program. Poor adherence was defined as completing less than 80 % of the approximately 20 prescribed weekly activities for two consecutive weeks during the 13-week treatment period. Baseline analgesic use was categorized into six groups: no medication, paracetamol (with/without dietary supplements), NSAIDs (with/without supplements), paracetamol combined with NSAIDs (with/without dietary supplements), dietary supplements only, and opioids (with/without other medications). Interval-censored parametric survival models adjusted for baseline characteristics were used for statistical analysis. In sensitivity analyses, alternative definitions of poor adherence were used. A complete case analysis was conducted as a subgroup analysis. Results: Compared to the no-medication group, individuals taking paracetamol-either alone (hazard ratio 0.94, 95 % CI 0.91, 0.98) or in combination with NSAIDs (0.91, 0.87, 0.94) reached poor adherence later. In contrast, opioid users (hazard ratio 1.12, 95 % CI 1.06, 1.19) reached poor adherence earlier. Adjusted median days to reach poor adherence ranged from 39.2 (95 % CI 36.9, 41.4) for opioids to 49.2 (47.7, 50.7) for paracetamol + NSAIDs users. Alternative definitions of poor adherence and a complete-case analysis generally yielded similar findings. Conclusion: Baseline use of paracetamol, alone or with NSAIDs, was associated with longer time to reach poor adherence, whereas opioid use predicted poor adherence earlier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.